TL;DR: A 2026 machine-learning study found that the final SNP-NF model in PLOS One reported mAUC 0.965, recall 0.929, and precision 0.929, while the study reported gains of about 3% in mAUC, 1% in precision, and 0.7% in recall versus their previous neural-process model. Key Findings SNP-NF performance was high: The final model reported mAUC …
TL;DR: A 2025 study in Neurochemistry International from Kindai University showed that oral arginine, a naturally occurring amino acid, blocked the formation of toxic amyloid-beta aggregates in lab tests and reduced amyloid pathology in two well-established mouse models of Alzheimer’s disease — with the authors flagging that the research-grade doses and methods are not equivalent …
TL;DR: A 2026 systematic review in The Cochrane Database of Systematic Reviews pooled 17 trials of anti-amyloid monoclonal antibodies (N=20,342 people with mild cognitive impairment or mild Alzheimer’s dementia) and concluded that any effect on memory decline or dementia severity was either nonexistent or well below the threshold considered clinically meaningful for patients. Key Findings …
TL;DR: A 2026 medRxiv preprint found that plasma p-tau217 AI models still separated amyloid-positive from amyloid-negative people across ADNI and A4, but calibration drift made the same probabilities less dependable for clinical decisions. Key Findings Calibration drift weakened clinical utility: The study trained plasma biomarker machine-learning models in one Alzheimer’s cohort and tested them in …
TL;DR: A 2026 systematic review and meta-analysis in Molecular Neurobiology found that plasma phosphorylated tau 217 (p-tau217), a blood marker of Alzheimer-linked tau pathology, identified biomarker-defined Alzheimer’s disease with pooled sensitivity of 85.4% and specificity of 88.0% across 27 studies. Key Findings 27-study evidence base: Researchers analyzed 19,652 participants from studies that compared plasma p-tau217 …
TL;DR: A 2026 medRxiv preprint tested SimulAD, an Alzheimer’s disease progression simulator, and reported that it reproduced mean amyloid-clearance results within 5% error across six major phase III anti-amyloid trials while also separating positive trials from null trials in retrospective power analyses. Key Findings Six phase III trials: Researchers retrospectively simulated TRAILBLAZER-ALZ2, CLARITY AD, EMERGE, …
TL;DR: A 2026 study in Nature Neuroscience from Baylor College of Medicine showed that boosting Sox9, a transcription factor that regulates aging astrocytes, improved astrocytes’ ability to clear amyloid plaques in Alzheimer’s mouse models and preserved cognitive function — pointing to a treatment strategy that targets the brain’s own support cells rather than directly attacking …
Blood GFAP Started Mirroring the Brain Only After the BBB Leaked TL;DR: Blood biomarkers mostly failed to mirror the brain while the blood-brain barrier stayed intact; once the barrier leaked, glial fibrillary acidic protein (GFAP), an astrocyte injury protein, and inflammatory signals started lining up across blood and cerebrospinal fluid (CSF), the fluid surrounding the …
TL;DR: A CAR-style therapy aimed at astrocytes turned brain support cells into amyloid cleaners, preventing plaque development and cutting existing plaque burden by about half in mice. Key Findings Plaque-free prevention arm: Young mice treated before plaques formed were reported plaque-free at nearly 6 months, when untreated Alzheimer-model mice are normally saturated. 50% plaque reduction: …
How Focused Ultrasound Reprogrammed Microglia in Alzheimer’s Rats TL;DR: In TgF344-AD rats, repeated low-intensity focused ultrasound triggered a short-lived inflammatory response, then left behind a more durable microglial metabolic shift in early disease without clearly improving Alzheimer’s pathology on its own. Key Findings 450 kPa across a 12 x 6 mm target: The team skull-corrected …
